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ABSTRACT 23 
Mycoplasma hyopneumoniae causes severe economic losses to the swine industry 24 
worldwide and the prevention of its related disease, enzootic porcine pneumonia, remains a 25 
challenge. The P97 adhesin protein of M. hyopneumoniae should be a good candidate for the 26 
development of a subunit vaccine because antibodies produced against P97 could prevent the 27 
adhesion of the pathogen to the respiratory epithelial cells in vitro. In the present study, a P97 28 
recombinant replication-defective adenovirus (rAdP97c) subunit vaccine efficiency was 29 
evaluated in pigs. The rAdP97c vaccine was found to induce both strong P97 specific 30 
humoral and cellular immune responses. The rAdP97c vaccinated pigs developed a lower 31 
amount of macroscopic lung lesions (18.5% ± 9.6) compared to the unvaccinated and 32 
challenged animals (45.8% ± 11.5). rAdP97c vaccine reduced significantly the severity of 33 
inflammatory response and the amount of M. hyopneumoniae in the respiratory tract. 34 
Furthermore, the average daily weight gain was slightly improved in the rAdP97c vaccinated 35 
pigs (0.672 kg/day ± 0.068) compared to the unvaccinated and challenged animals (0.568 36 
kg/day ± 0.104). A bacterin-based commercial vaccine (Suvaxyn® MH-one) was more 37 
efficient to induce a protective immune response than rAdP97c even if it did not evoke a P97 38 
specific immune response. These results suggest that immunodominant antigens other than 39 
P97 adhesin are also important in the induction of a protective immune response and should 40 
be taken into account in the future development of M. hyopneumoniae subunit vaccines. 41 
42 
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1. INTRODUCTION 43 
Mycoplasma hyopneumoniae is the etiological agent of enzootic
 
porcine pneumonia 44 
(PEP), which is one of the most economically significant
 
diseases found in the porcine 45 
industry worldwide [1]. The M. hyopneumoniae chronic infection is accompanied by non-46 
productive coughing, retarded growth and inefficient food conversion [1]. M. hyopneumoniae 47 
colonizes the ciliated epithelial cells of the respiratory tract, thereby damaging them [2, 3] 48 
and which predisposes infected animals to secondary invaders such as porcine reproductive 49 
and respiratory syndrome virus and Actinobacillus pleuropneumoniae [4, 5]. M. 50 
hyopneumoniae infection also causes an intensive inflammatory immune response in the 51 
bronchus-associated lymphoid tissue (BALT) which contributes to damage the lungs [6, 7].  52 
Traditionally, PEP is controlled using vaccines combined with hygiene and 53 
management procedures. As for many infectious diseases, the vaccination remains an 54 
effective approach to prevent and eradicate PEP. The commonly used vaccines against M. 55 
hyopneumoniae are in the form of bacterins. Several studies have demonstrated that these 56 
vaccines have a partial protective effect since vaccinated animals stay infected for a long 57 
period of time. Consequently, vaccines fail to prevent the transmission of the pathogen to 58 
susceptible animals [8, 9]. This partial protection could be due to the fact that bacterins are 59 
administered parenterally and, therefore, do not stimulate a strong mucosal immunity [10]. 60 
Current efforts to develop an effective vaccine against M. hyopneumoniae are shifted 61 
toward subunit-based vaccines. Some immunodominant antigens of the pathogen have been 62 
identified, and they include lipoproteins P65, Mhp378 and Mhp651 proteins [11, 12], the 63 
cytolosic P36 protein [13], ribonucleotide reductase (nrdF) [14] and the P97 adhesin [15]. 64 
However, only the nrdF and P97 proteins have been experimentally tested as subunit vaccine 65 
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candidates in pigs and were able to provide partial protection in vaccinated animals [16-18]. 66 
P97 fulfills important prerequisites for the development of an effective subunit vaccine. It is 67 
considered as a major adhesin of M. hyopneumoniae [15, 19], infected pigs develop immune 68 
responses against P97 and the antibodies produced against this protein prevent the adhesion 69 
of the pathogen to the respiratory epithelial cells in vitro[15]. Moreover, the encoding P97 70 
gene is found in all M. hyopneumoniae isolates tested so far [19, 20]. Furthermore, P97 is 71 
well characterized. P97 contains two repeat regions, RR1 and RR2, located in the C-terminal 72 
portion [21]. The cilium binding sites are located in the RR1 region and at least seven 73 
AAKPV/E repeats are required for functional binding [22]. The RR2 region is involved in 74 
the attachment of M. hyopneumoniae to the extracellular matrix of the respiratory tract [23]. 75 
As M. hyopneumoniae infection is restricted to the respiratory tract, an ideal subunit 76 
vaccine should be mucosally administered and should evoke both local humoral and cell-77 
mediated immune responses [16, 17]. One of the hallmark of the mucosal immune system is 78 
the production of secretory IgA (sIgA) which can prevent infection and favor the removal of 79 
the pathogens [10]. Recombinant adenovirus vectors (rAd) have a natural tropism for cells of 80 
mucosa such as the porcine respiratory tract [24-26].  In addition, rAd are 1) able to deliver 81 
efficiently the recombinant transgene(s) to the antigen-presenting cells; 2) able to induce both 82 
humoral and cellular specific immune responses against the recombinant expressed proteins; 83 
and 3) suitable for high-yield production in vitro [27, 28]. Considering these advantages, a 84 
recombinant replication-defective adenovirus vector expressing the C-terminal portion 85 
(containing the regions RR1 and RR2) of the P97 adhesin (P97c), designated rAdP97c, was 86 
previously generated and its immunogenicity was tested in mice [29].  87 
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Therefore, the objectives of the present study were (i) to evaluate the capacity of 88 
rAdP97c to induce a P97c specific immune response in pigs following mucosal 89 
administration, and (ii) to determine its protective efficacy in vaccinated pigs following a M. 90 
hyopneumoniae challenge infection. 91 
92 
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2. MATERIALS AND METHODS 93 
 94 
2.1. M. hyopneumoniae strains and proteins 95 
The M. hyopneumoniae strain used for the challenge was the virulent strain 232. This 96 
strain was cultured in modified Friis medium containing 20% porcine serum, 5% yeast 97 
extract, 150 g/mL bacitracin, 100 g/mL ampicillin, 7.5 g/mL colistin, 2.5 g/mL 98 
amphotericin B and 40 g/mL phenol red used as an indicator of growth. Bacteria were 99 
harvested and resuspended in phosphate buffered saline (PBS). The titer of M. 100 
hyopneumoniae was determined as described elsewhere [20], and expressed as color 101 
changing units (CCU) per mL. To extract total M. hyopneumoniae proteins, bacteria were 102 
resuspended in PBS containing 1mM PMSF and 1mM of pefabloc (Boehringer, Mannheim, 103 
Germany), and then lyzed on ice by sonication. The total protein extract was collected and 104 
kept at - 80°C until use.  105 
The recombinant P97c protein (rP97c) was produced in Escherichia coli strain 106 
BL2(DE3)pLysS as previously described [29]. Protein concentrations were determined using 107 
the Bradford method (Bio-Rad, Mississauga, ON, Canada). 108 
 109 
2.2. Vaccines 110 
The rAd used in this study was a replicative-defective E1 and E3 deleted human type 111 
5 (AdE1/E3). The rAdP97c vaccine designed to express the C-terminal portion of the M. 112 
hyopneumoniae P97 adhesin (P97c) of the 25934 strain (ATCC, Rockville, MD) was 113 
obtained from a previous study [29]. After amplification in 293 cells, the rAdP97c was purified 114 
by ultracentrifugation on double cesium chloride gradient, and frozen at - 80°C in PBS. The 115 
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titer of rAdP97c was determined using the 50% tissue culture infectious dose (TCID50) 116 
method. For comparison purposes, the commercially available bacterin-based vaccine, the 117 
Suvaxyn® MH-one (Wyeth Animal Health, Guelph, ON, Canada), was also included in this 118 
study. 119 
 120 
2.3. Vaccination and infection of pigs  121 
M. hyopneumoniae negative pigs (3 weeks old) were purchased from F. Menard Inc 122 
(Ange-Gardien, Québec, Canada) and maintained in the animal facility of the Canadian Food 123 
Inspection Agency (St-Hyacinthe, Québec, Canada). All experiments were conducted in 124 
accordance with the guidelines
 
and policies of the Canadian Council on Animal Care. A total 125 
of 28 pigs were included in the study and divided into four groups as follows: a) control 126 
group (non-vaccinated and non-challenged animals, n = 5); b) unvaccinated group (non-127 
vaccinated and challenged animals, n = 5); Suvaxyn® MH-one vaccinated group (animals 128 
were vaccinated once by intramuscular route, according to the manufacturer’s instructions 129 
and challenged, n = 8); d) rAdP97c vaccinated group (animals were vaccinated with 2 X 10
10 
130 
TCID50 of rAdP97c twice (at days 0 and 14) by intranasal (i.n.) route and challenged, n = 10). 131 
The challenge was performed at day 28 after the first vaccination with 10
6
 CCU of the 232 132 
M. hyopneumoniae strain by intratracheal route.  133 
Animals were weighed at days 0, 28, 42 and 56 after the first vaccination (post-134 
vaccination) to determine the average daily weight gain (ADG). All animals were euthanized 135 
at day 56 post-vaccination and lungs were removed to determine the percentage of 136 
macroscopic lung lesions as described elsewhere [30]. Sections of the lungs were also taken 137 
for microscopic examination and M. hyopneumoniae quantification.  138 
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 139 
2.4. Humoral immune response detection by ELISA 140 
Sera were collected at days 0, 14, 28, 42 and 56 and saliva at days 28 and 56 post-141 
vaccination. The HerdChek M. hyopneumoniae antibody ELISA kit (IDEXX Laboratories 142 
Inc., Westbrook, ME, USA) was performed to determine the serological status of pigs 143 
against M. hyopneumoniae antigens. According to the manufacturer's instructions, the 144 
tested samples are considered seropositive if the sample/positive control (S/P) ratio is 145 
higher than 0.3. For the detection of P97c-specific antibodies, polypropylene 96 wells 146 
plates (Nalge Numc International, Rochester, NY, USA) were coated with rP97c (0.5 147 
g/well) and incubated overnight at 4°C. The plates were washed with PBS containing 148 
0.05% Tween 20 (PBST) and blocked with 5% non-fat milk in PBS (PBSM). Following 149 
two wash steps with PBST, the plates were incubated with 100 l of sera or saliva (diluted 150 
1:200 in PBSM). Following three washes with PBST, the plates were incubated with 151 
horseradish peroxidase (HRP)-conjugated goat anti-porcine IgG or IgA (Bethyl 152 
Laboratories, Inc, Montgomery, TX, USA). In order to detect IgG subclasses, the plates 153 
were first incubated with mouse anti-porcine IgG1 or IgG2a (Serotec, Kidlington,
 
Oxford, 154 
England) before they were incubated with HRP-conjugated anti-mouse IgG heavy-plus-155 
light-chain (Serotec). After washing, 100 l/well of 3, 3’-5, 5’-tetramethyl benzedine 156 
(TMB) substrate (Zymed, San Francisco, CA, USA) were added. The color reaction was 157 
stopped following the addition of 1N H2SO4 and absorbance was read at 450 nm with an 158 
ELISA plate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA). The antibody titers 159 
were determined by extrapolation from standard curves which were generated with a pool 160 
of serum or saliva from rAdP97c vaccinated pigs as previously described [31]. 161 
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 162 
2.5. Lymphocyte proliferation assay 163 
Blood samples were taken (at days 0, 14, 28, 42 and 56) in heparinized tubes 164 
(Monoject, Mansfield, MA, USA). The peripheral blood mononuclear cells (PBMC) were 165 
purified by density gradient centrifugation using Ficoll-Hypaque-1077 (Sigma-Aldrich, 166 
Oakville, ON,
 Canada) according to the manufacturer’s instructions. The purified PBMC 167 
were resuspended at a concentration of 2 x 10
6
 cells/mL in RPMI 1640 culture medium 168 
supplemented with 10% of fetal bovine serum (FBS), 2 mM glutamine, 50 µM ß-169 
mercaptoethanol, and 100 U/mL penicillin/streptomycin. A 100 µl aliquot was dispatched 170 
into each well of a 96-well plate. One hundred µl of rP97c or total M. hyopneumoniae 171 
proteins (which both contain a total of 10 µg of protein/mL) were added to each well in 172 
triplicate. As a positive control, cells were also stimulated with Concanavalin (ConA) at a 173 
final concentration of 10 µg/mL. After 48 hrs incubation at 37°C with 5% CO2, cells were 174 
treated with 10 µM BrdU (Exalpha Biologicals Inc, MA. USA) and incubated for an 175 
additional period of 16 hrs. The cell incorporation of BrdU was measured using the BrdU 176 
Cell Proliferation Assay Kit (Exalpha Biologicals) according to the manufacturer’s 177 
instructions. The stimulation index (SI) was calculated by dividing the 450 nm absorbance 178 
results of the stimulated cells by the 450 nm absorbance results of the non-stimulated cells. 179 
 180 
2.6. Cytological and cytokine analysis in the BALF 181 
Bronchoalveolar lavage fluids (BALF) were collected at necropsy (day 56 after the 182 
first vaccination) as previously described [6]. Briefly, a volume of 30 mL of sterile PBS was 183 
infused into the lung using an 18-gauge catheter attached to a syringe. The BALF were 184 
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aspired back and passed through a single layer of gauze to remove gross mucus. 185 
Approximately 20 mL of the BALF was retrieved and immediately kept on ice. 186 
The number of total leukocytes was determined manually using a hemacytometer. 187 
The differential cell counts of leukocytes were made using the Shandon cytospin 4 machine 188 
(Shandon Inc., Pittsburgh, Pa, USA). The cells were stained by cytocentrifugation using the 189 
Diff-Quick staining method. For each sample, 400 to 500 cells/cytospin
 
were counted under 190 
the microscope.
 
191 
Cytokines (IL-1, IL-6, IL-8 and TNF-) were measured in the BALF by sandwich 192 
ELISA using porcine-specific pair-matched antibodies from R&D Systems (Minneapolis, 193 
MN, USA) according to the manufacturer’s recommendations. The concentration was 194 
determined after extrapolation from standard curves prepared using the related purified 195 
cytokines supplied by the manufacturer. All assays were carried out in duplicate.  196 
 197 
2.7. Quantification of M. hyopneumoniae in lungs and BALF 198 
In order to determine the amount of M. hyopneumoniae, sections of lungs were taken 199 
from individual pigs and were homogenized using the Mini-Beadbeater
TM
 homogenizer 200 
(Biospec products, Bartlesville, OK, USA). Homogenates and BALF, were clarified by 201 
centrifugation. Then, supernatants were collected and diluted serially from 10
1
 to 10
10
 in the 202 
growth medium of M. hyopneumoniae. For each dilution, a 200 µl aliquot was poured into 96 203 
well microplates in triplicate. The plates were covered with an adhesive film and incubated at 204 
37°C for 5 days. The amount of M. hyopneumoniae corresponds to the lower dilution where 205 
the color of medium changed from red to yellow and was expressed as CCU/mL. 206 
 207 
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2.8. In vitro M. hyopneumoniae growth inhibition assay 208 
The M. hyopneumoniae growth inhibition assay was performed as described 209 
previously with slight modifications [29]. Briefly, 100 µl aliquots containing 10
5 
CCU of the 210 
232 strain of M. hyopenumoniae were poured into 96 well microplates. One hundred µl of 211 
serial dilutions (1:40 to 1:1280) of serum samples (from day 28 post-vaccination) were then 212 
added into wells in triplicate. As positive controls, mycoplasma was cultured in the absence 213 
of serum. Wells containing only the culture medium served as negative controls. After 214 
incubation at 37°C for 4 days, absorbance was recorded at 560 nm. The percentage of growth 215 
inhibition was determined as follows: sample absorbance - absorbance of the positive 216 
control) / (negative control absorbance - absorbance of the positive control) x 100.  217 
 218 
2.9. Statistical analysis 219 
The statistical analyses were realized using the GraphPad Prism version 4 software. 220 
The paired t test was used to establish the differences between the level of IgG1 and IgG2a 221 
antibodies in pig sera and saliva of each experimental group. The one-way ANOVA 222 
combined with the Bonferroni post-tests models was used to determine if there is statistical 223 
significant difference in regards to the percentage of macroscopic lung lesions between 224 
experimental groups. The regular two-way ANOVA combined with the Bonferroni post-tests 225 
models was used in all others statistical analyses. Values of P < 0.05 were considered to be 226 
significant.  227 
228 
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3. RESULTS 229 
 230 
3.1. Humoral immunity in rAdP97c vaccinated pigs 231 
M. hyopneumoniae specific antibody response was analyzed by HerdChek M. 232 
hyopneumoniae Antibody ELISA kit ELISA from serum samples taken at day 0 (preimmune 233 
serum), 14, 28, 42 and 56 post-vaccination. As shown in Table 1, all pigs were negative at 234 
day 0, indicating that they were seronegative for the pathogen prior to the vaccination. The 235 
Suvaxyn® MH-one vaccinated animals showed a positive anti-M. hyopneumoniae antibody 236 
response before challenge. The unvaccinated pigs seroconverted following the challenge. In 237 
contrast, no antibody response could be detected neither in rAdP97c vaccinated nor non-238 
vaccinated and non-challenged animals. 239 
Significant levels of P97c-specific IgG and IgA were detected in sera of rAdP97c 240 
vaccinated pigs as early as day 14 post-vaccination (Fig. 1). P97c specific antibodies were 241 
also detected in unvaccinated animals after challenge, which indicates that the P97 adhesin 242 
was expressed in vivo during M. hyopneumoniae infection. The rAdP97c vaccinated pigs had 243 
significant levels of P97c-specific IgG and IgA (Fig. 1) in their saliva prior and after the 244 
challenge. No P97c specific antibody response was detected in the saliva of non-vaccinated 245 
and Suvaxyn® MH-one vaccinated animals prior to challenge but IgG and IgA were detected 246 
at 28 days post-challenge. Moreover, the level of saliva P97c specific IgA in Suvaxyn® MH-247 
one vaccinated animals was significantly lower compared to rAdP97c vaccinated animals at 248 
28 days post-challenge (P < 0.001). Both IgG subclasses were produced in sera and saliva of 249 
rAdP97c vaccinated animals, where a higher amount of IgG2a were produced compared to 250 
IgG1 (P < 0.05), suggesting a Th1-biased immune response (Fig. 2). Both IgG1 and IgG2a 251 
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P97c specific antibodies were found in unvaccinated and Suvaxyn® MH-one vaccinated 252 
animals only after challenge, with significantly higher amount of IgG1 compared to IgG2a (P 253 
< 0.001 and P < 0.01, respectively), indicating a Th2-biased immune response.  254 
 255 
3.2. Cell-mediated immune response following rAdP97c vaccination 256 
As illustrated in Fig. 3, only the rAdP97c vaccinated pigs PBMC, proliferated 257 
significantly in the presence of rP97c and the proliferation response was observed as early as 258 
day 14 post-vaccination (P < 0.001 at days 14, 28 and 42) and declined after the challenge (P 259 
< 0.05 at day 56). In contrast, significant SI were observed in the Suvaxyn® MH-one 260 
vaccinated animals only in the presence of M. hyopneumoniae cell lysate total proteins (Fig. 261 
3). The proliferation response in this group decreased after the challenge to a point that at day 262 
56 post-vaccination there was no statistical difference with the control group (P > 0.05). 263 
Interestingly, upon stimulation with ConA, no difference between the SI could be observed 264 
in all experimental groups before the challenge (days 14 and 28). However after the 265 
challenge, the SI of all challenged groups progressively decreased (Fig. 3). Taken together, 266 
these observations indicate that both rAdP97c and Suvaxyn® MH-one have the capacity to 267 
induce a cell-mediated immune response and that M. hyopneumoniae have the ability to 268 
induce an immunosuppression in infected animals which reduces the PBMC specific 269 
lymphocyte proliferation response against rP97c and M. hyopneumoniae cell lysate total 270 
proteins.  271 
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3.3. M. hyopneumoniae growth inhibition in vitro 275 
As shown in Fig. 4, sera from rAdP97c vaccinated pigs inhibited the growth of 276 
mycoplasma cells in a dose dependent manner. A significant mycoplasma growth inhibitory 277 
effect could also be observed within sera from animals vaccinated with Suvaxyn® MH-one 278 
and was higher compared to rAdP97c vaccinated animals. As expected, no mycoplasma 279 
growth inhibitory activity was observed within sera of non-vaccinated animals. 280 
 281 
3.4. Bacteriological and pneumonic findings 282 
One week after the challenge, a non-productive coughing was observed in all 283 
challenged groups with a lesser extend in Suvaxyn® MH-one vaccinated animals (data not 284 
shown). No macroscopic lung lesions were observed in the control animals group. In 285 
contrast, the pneumonic lesions characteristics of PEP were present in all infected animals 286 
(Fig. 5).  The unvaccinated and infected pigs had the higher percentage of pneumonic lesions 287 
(45.8% ± 11.5). In comparison to this group, the pigs vaccinated with rAdP97c and 288 
Suvaxyn® MH-one had significantly lower percentage of pneumonic lesions with means of 289 
18.5% ± 9.6 and 1.3% ± 1.7, respectively. No statistical difference was found between the 290 
uninfected animals and Suvaxyn® MH-one vaccinated and challenged animals. Noteworthy, 291 
a significant difference was observed between the infected and rAdP97c vaccinated animals 292 
compared to uninfected animals. After examining the microscopic lung lesions by 293 
hematoxylin-oesine staining, the presence of nodular lymphoid hyperplasia was observed 294 
around the bronchioles in the lung tissues from all challenged groups (data not shown). As 295 
expected no M. hyopneumoniae was recovered in the samples from the control group. In 296 
contrast, M. hyopneumoniae was retrieved in all challenged animals, but significantly at 297 
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lower amount in rAdP97c and Suvaxyn® MH-one vaccinated animals compared to 298 
unvaccinated animals (P < 0.05 and P < 0.001, respectively) (Fig. 5). The amount of M. 299 
hyopneumoniae retrieved in BALF and lungs from Suvaxyn® MH-one vaccinated animals 300 
was significantly lower than in rAdP97c vaccinated animals (P < 0.001 and P < 0.01, 301 
respectively).  Overall, the amount of M. hyopneumoniae retrieved from lungs of infected 302 
animals was higher compared to BALF (P < 0.001). 303 
 304 
3.5. Growth performance of rAdP97c vaccinated pigs 305 
As illustrated in Fig. 5, means ADG were not significantly different between the 306 
experimental groups before challenge. However, unvaccinated and rAdP97c vaccinated 307 
challenge animals displayed a significant retarded growth at day 42 post-vaccination 308 
compared to the control group (P < 0.01). At 42 days post-vaccination, no significant 309 
difference could be observed with Suvaxyn® MH-one vaccinated animals compared to the 310 
control, the unvaccinated and the rAdP97c vaccinated challenge groups.  Furthermore, at the 311 
end of the experiment (day 56 post-vaccination), there was no statistical difference with the 312 
ADG values of Suvaxyn® MH-one vaccinated and infected animals (ADG = 0.743 ± 0.088 313 
kg/day) compared to the control (ADG = 0.830 ± 0.037 kg/day) and rAdP97c vaccinated 314 
challenge animals (ADG = 0.657 ± 0.079 kg/day). There was no statistical difference in the 315 
ADG values between the unvaccinated and rAdP97c vaccinated challenge animals during the 316 
course of the experiment but there were significant differences when they were compared to 317 
control animals at days 42 and 56 post-vaccination. Nonetheless, the mean ADG value of 318 
rAdP97c vaccinated animals was slightly higher compared to unvaccinated animals with the 319 
consequence that Suvaxyn® MH-one vaccinated animals ADG value was statistically 320 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
different from unvaccinated animals (P < 0.01) but was not statistically different from 321 
rAdP97c vaccinated animals (Fig. 5). Overall, these results suggest that rAdP97c vaccine has 322 
a beneficial effect on the growth performance of pigs but at a lower extend than Suvaxyn® 323 
MH-one vaccine. 324 
 325 
3.6. Inflammatory responses 326 
As illustrated in Fig. 6, significant increases of total leukocytes were observed in 327 
unvaccinated (401.3 X 10
4
 ± 187.0 cells/mL) and rAdP97c vaccinated challenge animals 328 
(253.7 X 10
4
 ± 79.3 cells/mL) compared to the control group (19.5 X 10
4
 ± 2.1 cells/mL). 329 
These increases were in average 20-fold for the unvaccinated group, 13-fold for rAdP97c 330 
vaccinated challenge animals. There was a significant increase of neutrophils in the BALF 331 
from unvaccinated (264.0 X 10
4
 ± 68.9 cells/mL) and rAdP97c vaccinated challenge animals 332 
(158.6 X 10
4
 ± 82.5 cells/mL) compared to the control group (0.570 X 10
4
 ± 0.212 cells/mL). 333 
These latest results indicate that M. hyopneumoniae infection causes an important 334 
inflammatory immune response in the lungs. In addition, even if rAdP97c has a tendency to 335 
reduce the migration of neutrophils into the M. hyopneumoniae infected lungs compared to 336 
unvaccinated animals (only if the mean values are compared), it was not able to prevent the 337 
inflammatory immune response efficiently compared to Suvaxyn® MH-one commercial 338 
vaccine. Furthermore, in comparison to the control group and the Suvaxyn® MH-one 339 
vaccinated challenge animals, significant levels of IL-6 and IL-8 were detected in 340 
unvaccinated and rAdP97c vaccinated challenge animals (P < 0.001) (Fig. 6). In addition, no 341 
significant differences were observed in the levels of IL-1, IL-6, IL-8 and TNF with the 342 
uninfected and unvaccinated animals (control group) compared to Suvaxyn® MH-one 343 
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vaccinated challenge animals which clearly support the fact that this commercial vaccine 344 
efficiently prevented the inflammatory immune response. Noteworthy, the rAdP97c 345 
vaccination was able to reduce the IL-8 expression in infected animals compared to 346 
unvaccinated challenge animals (P < 0.001) (Fig. 6). 347 
348 
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4. DISCUSSION 349 
 350 
M. hyopneumoniae is the causative agent of PEP, which is one of the most contagious 351 
diseases in the swine industry [1]. As for many infectious diseases, vaccination remains the 352 
effective approach for preventing and eradicating PEP. Extensive efforts are currently 353 
oriented toward the development
 
of subunit vaccines to address the shortcomings associated 354 
with the current bacterin-based commercial vaccines [16-18]. Herein, a replication-defective 355 
recombinant adenovirus-based vaccine encoding the C-terminal portion of the M. 356 
hyopneumoniae P97 adhesin protein (rAdP97c) was developed. The C-terminal portion of the 357 
P97 adhesin contains two regions called RR1 and RR2 that allow the adherence of the 358 
pathogen to host cells [22, 23]. The rAdP97c vaccine was assessed (i) for its capacity to 359 
induce a P97c-specific immune response in pigs, and (ii) for its protective efficacy in 360 
vaccinated pigs in a M. hyopneumoniae challenge trial. A bacterin-based commercial 361 
vaccine, the Suvaxyn® MH-one, was also included in the study as a vaccine control.  362 
In the present study, it was found that rAdP97c i.n. inoculation was able to induce a 363 
specific mucosal as well as systemic immune responses in pigs against P97c recombinant 364 
protein which was characterized by the production of high levels of P97c specific IgG (with 365 
the IgG2a response dominated over the
 
IgG1 response) and IgA antibodies in the sera and 366 
saliva of vaccinated animals, even before M. hyopneumoniae challenge (Fig. 1). Previous 367 
studies have also demonstrated that i.n. immunization with rAd vectors stimulates both 368 
mucosal
 
and systemic antibody responses to the encoded antigen and preferentially promotes 369 
a Th1-type immune response [32-34]. It is not
 
known whether the pigs have a Th1/Th2 370 
system similar to the one described in mice [35]. Nevertheless, it is tempting to speculate that 371 
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immunization
 
with rAdP97c triggers a substantial P97c-specific Th1-type response and a 372 
moderate Th2-type response in vaccinated pigs (Fig. 2).  373 
The actual contribution of both types of immune response in the protection against M. 374 
hyopneumoniae infections is not clearly defined. The first vaccination trial using a 375 
recombinant P97 protein administered intramuscularly failed to protect the vaccinated pigs 376 
against M. hyopneumoniae [36]. Shimoji et al. evaluated Erysipelothrix rhusiopathiae YS-19 377 
expressing the C-terminal portion of P97 as an i.n. administered vaccine against M. 378 
hyopneumoniae. They observed a significant reduction of macroscopic pneumonic lesions 379 
despite the fact that this vaccine failed to induce detectable antibodies against P97 [17]. On 380 
the other hand, Thacker et al. have tested different bacterin-based vaccines against M. 381 
hyopneumoniae, and found that the humoral immunity appeared to correlate substantially 382 
with the reduction of the percentage of pneumonic lesions compared to the cell-mediated 383 
immunity [37]. It has been reported that local sIgA prevents the adhesion of mycoplasmas to 384 
host cells, and IgG enhances their phagocytosis and opsonization [38, 39]. In a previous 385 
study, it was shown that sera of rAdP97c immunized mice were able to prevent the growth of 386 
M. hyopneumoniae in vitro but not sera of nrAd immunized mice [29] which have suggested 387 
that specific P97c antibodies could be involved in that phenomenon. Herein, sera of rAdP97c 388 
and Suvaxyn® MH-one vaccinated pigs were also able to inhibit the growth of M. 389 
hyopneumoniae in vitro (Fig. 4). A specific cell-mediated immune response against P97c was 390 
also detected in PBMC of rAdP97 vaccinated pigs but not in PBMC of Suvaxyn® MH-one 391 
vaccinated pigs (Fig. 3). Given the propensity of M. hyopneumoniae for the suppression of 392 
cell-mediated immune response [16, 18, 40], it was not suprising that PBMC from the M 393 
hyopneumoniae infected animals showed a decreased SI when stimulated in vitro with ConA 394 
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and all tested antigens (rP97c and M hyopneumoniae cell lysate total protein) (Fig. 3). 395 
Noteworthy, the mechanism by which the pathogen induces the PBMC cell-mediated 396 
immunosuppression is not known. Since the immunosuppressive effect was observed in 397 
PBMCs, this may be due mainly to the regulation
 
of the immune response of the host rather 398 
than a direct effect
 
of the bacterium [41]. 399 
To evaluate whether P97c-specific immune response was protective, the vaccinated 400 
pigs were challenged. Interestingly, the rAdP97c vaccination had a positive effect against M. 401 
hyopneumoniae challenge by lowering the amount of M. hyopneumoniae recovered from 402 
tissues (Fig. 5). There was a significant reduction of M. hyopneumoniae amount recovered 403 
from the respiratory tract (in lungs and BALF) and a significant reduction of the percentage 404 
of macroscopic lung lesions in rAdP97c vaccinated animals (Fig. 5). Furthermore, the 405 
rAdP97c vaccinated group also had an average ADG higher than the unvaccinated group, 406 
although there was no statistical difference between both groups. In addition, more 407 
neutrophils were detected in the BALF of the unvaccinated challenge group than in the 408 
rAdP97c vaccinated and challenge group (Fig. 6), indicating that inflammatory response was 409 
milder in animals vaccinated with rAdP97c. IL-8 acts primarily on the activation and 410 
migration of neutrophils [42]. Therefore, it was not surprising that BALF of the unvaccinated 411 
challenge animals showed a higher concentration of IL-8 than rAdP97c vaccinated animals 412 
(Fig. 6). M. hyopneumoniae infection is well known to increase cytokines expression, such as 413 
IL-1, IL-6, IL-8 and TNF- [43].  In the previous published reports, several approaches 414 
were used to detect those cytokine expressions such as bioassay, qPCR for mRNA expression 415 
and ELISA.  If we take into account the technique that was presently used (ELISA), the type 416 
of sample tested (BALF) and the time post-infection (28 days post-infection), the level of IL-417 
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1, IL-6, IL-8 and TNF- expression detected in BALF of M hyopneumoniae infected 418 
animals is in accordance with a previous report published by Thanawongnuwech et al. 419 
(2004). 420 
For all protection criteria evaluated in the present study, rAdP97c was less efficient than 421 
the Suvaxyn® MH-one vaccine. The fact that Suvaxyn® MH-one vaccine contains several 422 
immunodominant antigens of M. hyopneumoniae may explain its superiority over the rAd97c 423 
subunit vaccine but at least P97c protein alone is able to induce a partial protective immune 424 
response by reducing 1) the macroscopic lung lesions; 2) the amount of M. hyopneumoniae 425 
recovered from tissues and 3) the local inflammation. On the other hand, the M. hyopneumoniae 426 
challenge strain used, the heterologous 232 strain, may also have an effect on the efficacy of 427 
rAdP97c. Indeed, the homologous ATCC 25934 (where the P97c gene originate) and the 232 428 
strain differ in the number of the AAKPV/E repeat sequence: 15 for the 232 strain and 10 for the 429 
ATCC 25934 strain (data not shown). From the obtained results rise several questions. 1) Is it 430 
possible to generate a very efficient vaccine against M. hyopneumoniae with a subunit vaccine 431 
comprised of a single antigen? 2) What is the importance of the antigenic variations including 432 
that of the P97 adhesin in regards to the protective immune response? 433 
In conclusion, our results demonstrate that the rAdP97c vaccine induces high P97c 434 
specific cell-mediated and humoral immune responses and partially protects the pigs against 435 
M. hyopneumoniae challenge. However, further studies are necessary to improve this subunit 436 
vaccine approach which should involve the inclusion of other M. hyopneumoniae antigens in 437 
addition to the P97c protein.  438 
439 
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Table 1.  HerdChek M. hyopneumoniae Antibody ELISA assay antibodies detection results.  
Experimental groups Day 0 Day 14 Day 28 Day 42 Day 56
Control (n = 5) 0.013 ± 0.015 0.026± 0.057 0,042 ± 0,027 0.044 ± 0.021 0,062 ± 0,014
Unvaccinated (n = 5) 0,028 ± 0,025 0.028 ± 0.024 0.022 ± 0,019 0.194 ± 0.083 0.36 ± 0,182
Suvaxyn® MH-one (n =8) 0,029 ± 0,024 0,24 ± 0.019 0,455 ± 0,164 1,3 ± 0,426 0.75 ± 0,501
rAdP97c (n = 10) 0,026 ± 0,013 0.044 ± 0.104 0,055 ± 0,085 0.154 ± 0,094 0.096 ± 0.084
Sample/positive control (SP) ratio ± standard deviation (SD)
a
The pigs were vaccinated with rAdP97c (at days 0 and 14) or Suvaxyn® MH-one (at day 0), and challenged with the virulent M. hyopneumoniae 
232 strain at day 28 post-vaccination (after the first vaccination). Sera were collected at days 0, 14, 28, 42 and 56 post-vaccination and examined for 
the presence of antibodies against M. hyopneumoniae. 
a
 seropositive if the S/P ratio is greater than 0.3. 
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FIGURE LEGENDS 
 
Fig.1. P97c-specific IgG and IgA antibodies production in vaccinated pigs.  Pigs were 
unvaccinated or vaccinated with rAdP97c (at days 0 and 14) or Suvaxyn® MH-one (at 
day 0) and challenged with the virulent M. hyopneumoniae 232 strain at day 28 post-
vaccination. ELISA assays were performed using the rP97c as an antigen with sera and 
saliva. When 2 sets of data are labeled with superscripts of different letters or when only 
one set is labeled with a superscript, it indicates that these 2 sets of data are statistically 
different (P < 0.05). 
 
Fig.2. P97c specific IgG1 and IgG2a antibodies production in vaccinated pigs.  
ELISA assays were performed using rP97c as an antigen and with sera and saliva. 
Experimental groups: unvaccinated and uninfected control animals (Ctl); unvaccinated 
and infected animals (Unvac); Suvaxyn® MH-one vaccinated and infected animals (MH-
one); rAdP97c vaccinated and infected animals (rAdP97c). *P < 0.05; **P < 0.01; *** P 
< 0.001 (significant difference between IgG1 and IgG2a).  
 
Fig. 3. P97c specific lymphocyte proliferation immune responses.  The PBMC were 
stimulated with rP97c or with the total mycoplasma cell lysate proteins or with 
Concanavalin A. The lymphocyte proliferation responses were measured as described in 
materials and methods. Data are expressed as stimulation index (SI) which represent the 
ratio of the BrdU cell incorporation of the stimulated cells divided by the BrdU cell 
incorporation of the non-stimulated cells (see materials and methods section). When 2 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 30 
sets of data are labeled with superscripts of different letters or when only one set is 
labeled with a superscript, it indicates that these 2 sets of data are statistically different (P 
< 0.05). 
 
Fig. 4. Growth inhibition of M. hyopneumoniae by sera of vaccinated pigs.  
Mycoplasma cells (10
5 
CCU) were cultured as described in materials and methods in the 
presence of serial dilutions of sera collected at day 28 post-vaccination. The percentage 
of growth inhibition was determined as follows: absorbance sample - absorbance of 
positive control) / (absorbance of negative control - absorbance positive control) x 100. 
 
Fig. 5. Level of protection induced in rAdP97c vaccinated pigs.  Experimental groups: 
unvaccinated and uninfected control animals (Ctl); unvaccinated and infected animals 
(Unvac); Suvaxyn® MH-one vaccinated and infected animals (MH-one); rAdP97c 
vaccinated and infected animals (rAdP97c). BALF: bronchoalveolar lavage fluid; CCU: 
color changing unit; ADG: average daily weight gain. When 2 sets of data are labeled 
with superscripts of different letters or when only one set is labeled with a superscript, it 
indicates that these 2 sets of data are statistically different (P < 0.05). 
 
Fig. 6. Inflammatory immune responses in the bronchoalveolar lavage fluids.  BALF 
were collected at necropsy as described in the materials and methods section. 
Macrophages (Mac); neutrophils (Neu); lymphocytes (Lym). When 2 sets of data are 
labeled with superscripts of different letters or when only one set is labeled with a 
superscript, it indicates that these 2 sets of data are statistically different (P < 0.05). 
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